| MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. | prostate, |
| E2F1-dependent oncogenic addiction of melanoma cells to MDM2. | skin, |
| Identification of spliced variants of the proto-oncogene HDM2 in colorectal cancer. | colorectal, |
| MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells. | neuroblastoma, |
| MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer. | breast, |
| The MDM2 oncogene is amplified in a substantial proportion of ER+ early-stage breast carcinomas and an independent parameter for poor patient outcome in this subgroup. | breast, |
| Human Oncoprotein MDM2 Up-regulates Expression of NF-kappaB2 Precursor p100 Conferring a Survival Advantage to Lung Cells. | lung, |
| FEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma. | nasopharyngeal,laryngeal, |
| MDM2 oncogene, E3 ubiquitin protein ligase T309G polymorphism and risk of oesophageal or gastric cancer: meta-analysis of 15 studies. | gastric,esophageal, |
| Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways. | lymphoma, |
| Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action. | liver,oral,prostate, |
| The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer. | breast, |
| Results suggest that inhibition the expression of c-mdm2 proto-oncogene protein (MDM2) might be a potential target in non-small cell lung cancer (NSCLC) treatment. | lung, |
| the present study is the first to provide evidence suggesting that miR610 directly targets MDM2 proto-oncogene E3 ubiquitin protein ligase to function as a tumor suppressor in glioma. | glioma, |
| Brain-specific angiogenesis inhibitor 1 (BAI1) prevents proto-oncogene Protein c-mdm2 (Mdm2)-mediated tumor supressor p53 (p53) polyubiquitination, and its loss substantially reduces p53 levels. | brain, |
| G protein-coupled receptor family C group 5 member A (GPRC5A) deficiency contributes to dysregulated proto-oncogene protein c-mdm2 (MDM2) via activated epidermal growth factor receptor (EGFR) signaling, which promotes lung tumor development. | lung, |
| Investigation of MDM2 Oncogene Copy Number Alterations in Cases of Chronic Lymphocytic Leukemia. | leukemia, |
| Knockdown of CALB1 inhibited the proliferation and colony formation of ovarian cancer cells. CALB1 interacts with MDM2 protooncogene (MDM2) and promoted the interaction between p53 and MDM2. | colorectal,ovarian, |
| Interaction between the retinoblastoma protein and the oncoprotein MDM2. | retinoblastoma, |
| Use of representational difference analysis for the identification of mdm2 oncogene amplification in diethylstilbestrol-induced murine uterine adenocarcinomas. | uterine, |